Celcuity Inc. (CELC) is a pre-revenue clinical-stage oncology company with a single asset, gedatolisib, currently under FDA NDA review (PDUFA date July 17, 2026). Under a liquidation lens as of March 31, 2026, recovery to equity is deeply negative. The MFFAIS-computed liquidation values (CLV, LLV, OLV) are all reported at approximately -$16.1 million, which understates the true deficit because the model appears to be capturing only a partial slice of the liability stack or applying a simplified methodology. A practitioner reconstruction from the filing narrative yields a more severe picture. Liquid assets consist of $145.2 million in cash and cash equivalents plus $241.9 million in short-term investments (U.S. treasury securities), totaling $387.1 million, all recoverable at or near par under liquidation. Tangible non-current assets are de minimis — PP&E and capitalized software are negligible (Q1 capex of $0.3 million; no material fixed asset base disclosed). Intangibles and the Pfizer license (carried at zero after expensing) receive a 0% recovery haircut. Against these assets, the liability stack at face value is substantial. The July 2025 convertible notes carry $201.3 million face principal maturing August 1, 2031, with a carrying value of $195.6 million as of March 31, 2026 (net of $6.4 million unamortized issuance costs). The Amended A&R Loan Agreement (Oxford/Innovatus) carries $130.0 million face principal plus a $5.85 million final fee and $2.0 million accrued PIK interest, with net carrying value of $127.9 million and future scheduled principal payments of $137.9 million (including final fee and PIK). Combined gross debt obligations exceed $339 million at face. Adding operating liabilities (accrued clinical trial costs, accounts payable, operating lease obligations — not separately quantified in the truncated XBRL but disclosed in MD&A as material working capital items), total obligations comfortably exceed liquid assets. The accumulated deficit stands at $501.7 million. Net cash used in operations was $55.1 million in Q1 2026, up 54% from $35.9 million in Q1 2025, driven by SG&A expansion (+174% YoY) as the company pre-builds a commercial organization ahead of potential FDA approval. Q1 2026 net loss was $52.8 million versus $37.0 million in Q1 2025. The filing discloses up to $370 million in additional contingent debt capacity (Term E up to $100M, Term F up to $120M, Term G up to $150M), none of which is currently drawn but which would further burden recovery if drawn before any hypothetical liquidation. The Pfizer license agreement contains up to $335 million in contingent milestone obligations; the $5.0 million NDA filing milestone was paid in January 2026 and is not a future liability. Royalty obligations on product sales would only arise post-commercialization. The filing does not separately disclose total operating lease liabilities as a standalone XBRL-tagged figure in the provided TAG_CONTEXT. No prior-period XBRL TAG_CONTEXT is available for direct tag-level comparison. TAG_CONTEXT for this filing is empty — no XBRL tags were provided — so no tag-level insights can be generated per the applicable rules. All quantitative observations above are drawn from the filing narrative and MD&A. The company states it believes current resources fund operations through 2027, which is a going-concern solvency statement, not a liquidation recovery statement. On a liquidation basis today, equity recovery is negative by an amount in the range of negative $50 million to negative $100 million or worse depending on working capital settlement assumptions, with the convertible notes and term loans constituting the primary liability overhang against a primarily liquid asset base.
▼ Community Notes